Amarin Corp Plcuk (AMRN) Shares Outstanding (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Shares Outstanding (Entity) of $436.2 million for Q2 2026, up 1.76% year-over-year from $428.7 million in Q2 2025, and little changed quarter-over-quarter from $435.5 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Shares Outstanding (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Shares Outstanding (Entity) for 17 consecutive years, with $436.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 1.76% year-over-year to $436.2 million; the TTM figure through Jun 2026 stood at $436.2 million (up 1.76% YoY), while the FY2025 annual figure was $429.8 million, down 94.77% from the prior year.
- Shares Outstanding (Entity) steadied at $436.2 million in Q2 2026 per AMRN's latest filing, from $435.5 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $8.4 billion in Q3 2024 and bottomed at $410.1 million in Q1 2024.
- Historically, Shares Outstanding (Entity) has averaged $5.2 billion across 5 years, with a median of $8.2 billion in 2022.
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) plunged 95.07% — and 2025, when it increased 4.07%.
- Amarin Corp Plc\Uk's Shares Outstanding (Entity) stood at $8.2 billion in 2022, then grew by 1.41% to $8.4 billion in 2023, then decreased by 1.72% to $8.2 billion in 2024, then sank by 94.77% to $429.8 million in 2025, then grew by 1.49% to $436.2 million in 2026.
- Business Quant data shows AMRN's Shares Outstanding (Entity) at $436.2 million in Q2 2026, $435.5 million in Q1 2026, and $429.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.41 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.55 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 540.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.03 Bn |
| 10 | Amarin Corp Plcuk | 5.86 Bn | 5.54 Bn | 14.99 Mn | 416.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 416.44 Mn |
| Mar 31, 2026 | 419.05 Mn |
| Dec 31, 2025 | 414.98 Mn |
| Sep 30, 2025 | 415.53 Mn |
| Jun 30, 2025 | 414.48 Mn |
| Mar 31, 2025 | 413.42 Mn |
| Dec 31, 2024 | 8.22 Bn |
| Sep 30, 2024 | 8.22 Bn |
| Jun 30, 2024 | 8.22 Bn |
| Mar 31, 2024 | 410.15 Mn |
| Dec 31, 2023 | 8.15 Bn |
| Sep 30, 2023 | 8.17 Bn |
| Jun 30, 2023 | 8.16 Bn |
| Mar 31, 2023 | 8.12 Bn |
| Dec 31, 2022 | 8.02 Bn |
| Sep 30, 2022 | 8.09 Bn |
| Jun 30, 2022 | 7.96 Bn |
| Mar 31, 2022 | 7.96 Bn |
| Dec 31, 2021 | 7.92 Bn |
| Sep 30, 2021 | 7.93 Bn |